NEW YORK, Nov. 30, 2021 /CNW/ -- Mind Medicine
(MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ); (the
"Company"), a leading biotech company developing
psychedelic-inspired therapies, is pleased to announce the
publication of the first data on the interaction of the selective
serotonin uptake inhibitor (SSRI) escitalopram with the acute
response to psilocybin in humans. The publication resulted from a
randomized, double-blind, placebo-controlled, crossover
pharmacology study in healthy volunteers conducted by the
University Hospital Basel Liechti Lab and sponsored by MindMed.
The study found that escitalopram pre-treatment had no relevant
impact on positive mood effects of psilocybin but significantly
reduced negative effects like anxiety and adverse cardiovascular
reactions, compared with placebo pre-treatment in the study's
healthy volunteers. Escitalopram did not alter the pharmacokinetics
of psilocin. Escitalopram did not alter QTc intervals or
circulating BDNF levels before or after psilocybin administration.
The study was published in Clinical Pharmacology and
Therapeutics. The full-text can be accessed here:
https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.2487
"Two key questions arise around the use of psilocybin in
patients undergoing antidepressant treatment," said Prof.
Matthias Liechti, the principal
investigator of the study. "First, for safety reasons, should a
patient stop using antidepressants before receiving psilocybin?
Second, if there is no safety risk, will the antidepressant reduce
the patient's response to psilocybin? These results indicate that
psilocybin may be dosed during escitalopram treatment without
apparent impact on the effect of psilocybin. Thus, the study
answers the first question and provides a positive indication for
the second."
The study results highlight important areas for future research.
Dr. Miri Halperin Wernli, Executive
President of MindMed, added: "If the results are confirmed in
subsequent studies, with other substances and in patients rather
than healthy individuals, antidepressants may no longer need to be
stopped for psilocybin treatment. Further studies are needed with a
longer antidepressant pre-treatment time and patients with
psychiatric disorders to further define interactions between
antidepressants and psilocybin or other psychedelics."
Forward-Looking Statements
Certain statements in this news release related to the Company
constitute "forward-looking information" within the meaning of
applicable securities laws and are prospective in nature.
Forward-looking information is not based on historical facts, but
rather on current expectations and projections about future events
and are therefore subject to risks and uncertainties which could
cause actual results to differ materially from the future results
expressed or implied by the forward-looking statements. These
statements generally can be identified by the use of
forward-looking words such as "will", "may", "should", "could",
"intend", "estimate", "plan", "anticipate", "expect", "believe",
"potential" or "continue", or the negative thereof or similar
variations. Forward-looking information in this news release
include, but are not limited to, statements regarding the safety,
effects and benefits of escitalopram pre-treatment and the acute
response to psilocybin in humans, the results for future studies
and the need for antidepressants to be stopped for psilocybin
treatment. Although the Company believes that the expectations
reflected in such forward-looking information are reasonable, such
information involves risks and uncertainties, and undue reliance
should not be placed on such information, as unknown or
unpredictable factors could have material adverse effects on future
results, performance or achievements of the Company. There are
numerous risks and uncertainties that could cause actual results
and the Company's plans and objectives to differ materially from
those expressed in the forward-looking information, including
history of negative cash flows; limited operating history;
incurrence of future losses; availability of additional capital;
lack of product revenue; compliance with laws and regulations;
difficulty associated with research and development; risks
associated with clinical trials or studies; heightened regulatory
scrutiny; early stage product development; clinical trial risks;
regulatory approval processes; novelty of the psychedelic inspired
medicines industry; as well as those risk factors discussed or
referred to herein and the risks described under the headings "Risk
Factors" in the Company's filings with the securities regulatory
authorities in all provinces and territories of Canada which are available under the
Company's profile on SEDAR at www.sedar.com and with the U.S.
Securities and Exchange Commission on EDGAR at www.sec.gov. Should
one or more of these risks or uncertainties materialize, or should
assumptions underlying the forward-looking information prove
incorrect, actual results and future events could differ materially
from those anticipated in such information. Although the Company
has attempted to identify important risks, uncertainties and
factors that could cause actual results to differ materially, there
may be others that cause results not to be as anticipated,
estimated or intended. These and all subsequent written and oral
forward-looking information are based on estimates and opinions of
management on the dates they are made and are expressly qualified
in their entirety by this notice. Except as required by law, the
Company does not intend and does not assume any obligation to
update this forward-looking information.
Media Contact: mindmed@150bond.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/mindmed-and-liechti-lab-publish-first-human-data-on-the-interacting-effects-of-an-ssri-and-psilocybin-301433726.html
SOURCE Mind Medicine (MindMed) Inc.